Aduro shows survival benefit with pancreatic cancer vaccine duo
This article was originally published in Scrip
Executive Summary
Private US biotech company Aduro BioTech has reported a survival benefit in metastatic pancreatic cancer with its combination immunotherapy-based treatment, in a Phase II trial that was stopped early on the strength of the data after a pre-planned interim analysis.
You may also be interested in...
Immuno-Oncology's Next Wave: Key Targets And Emerging Players
Doesn't every biopharma company have an immuno-oncology strategy these days? It certainly seems that way, considering the number of drug developers that are labeling their therapeutic candidates as immunotherapies regardless of whether the description truly fits their asset.
Urovant’s Vibegron Flops In IBS Study
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Deal Watch: Bristol Teams Up With Insitro, Sensyne In AI-Directed Collaborations
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Need a specific report? 1000+ reports available
Buy Reports